Insulet/$PODD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Ticker

$PODD
Sector
Primary listing

Employees

3,900

Insulet Metrics

BasicAdvanced
$24B
102.29
$3.32
1.35
-

What the Analysts think about Insulet

Analyst ratings (Buy, Hold, Sell) for Insulet stock.

Bulls say / Bears say

Insulet reported Q2 2025 revenue of $649.1 million, a 32.9% increase year-over-year (31.3% on a constant currency basis), and improved its gross margin by 190 basis points to 69.7%, surpassing previous guidance. This strong performance led the company to raise its full-year revenue growth outlook to a range of 24%–27% (Business Wire).
The Omnipod 5 App for iPhone is now fully available with integrated Dexcom G7 CGM compatibility, establishing Insulet as the first to offer a tubeless automated insulin delivery system controllable through both Android and iOS smartphones. This development broadens patient options and differentiates Insulet in the automated insulin delivery market (Business Wire; FT).
Insulet has accelerated its international growth by launching Omnipod 5 commercially in nine new countries, including Australia, Belgium, Canada, and Switzerland. The company is also advancing its new manufacturing facility in Malaysia, strengthening its global supply chain and supporting ongoing expansion (Business Wire).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

Insulet Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Insulet Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PODD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs